Acquisitions vs FDA Actions
Side-by-side coverage analysis for Acquisitions and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Acquisitions
M&A activity
- Stories
- 13
- Avg Impact
- 6.8/10
- Dominant Tone
- Bullish
- Latest
- 2d ago
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 20
- Avg Impact
- 7/10
- Dominant Tone
- Bullish
- Latest
- 2d ago
Recent Headlines
Acquisitions
- Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60
- Partnered Health breach puts patient data at risk amid Bupa takeover
- Post-Acquisition Blow: 23andMe Buyer Hit with $47M Genetic Data Breach Fine
- Biolife’s $1B+ Takeover Potential Reshapes Cell Therapy Supply Chains
- $870M AMS Acquisition: H.B. Fuller Captures Tissue-Healing Tech Portfolio
- GeneDx Impairment Sparks Biotech Securities Suit: $31.3M Charge on AI Acquisition
- Animal Health RFID: AEG ID Acquisition Targets Tens of Millions of Transponders
- Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster Oncology Pipeline
- Merck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff
- Wellgistics Health Signs $105M LOI to Acquire Neuritek Therapeutics
FDA Actions
- Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
- Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
- Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says
- Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void
- Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
- HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
- AIIMS Recruits 460+ Researchers, Supercharging India’s Biomedical Pipeline
- First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status
- Roundup Ruling: 7-2 SCOTUS Verdict Reduces Bayer's Liability by Billions
- $6.5B Fraud Sweep Nabs Genetic Testing Scams: Biotech’s Compliance Wake-Up Call